Units are fixed. Waste is the variable.
Think in two costs. Purchased cost per unit is what you pay the distributor, net of rebates — call it roughly $5.25 to $6.00 a unit depending on your tier and loyalty capture. Realized cost per unit is purchased cost divided by the units you actually bill. The gap between them is waste, and most owners never measure it.
The waste lives in places nobody writes down:
- Hub and needle dead space. Every draw leaves roughly 0.05–0.07 mL trapped in the syringe hub and needle. The more concentrated your reconstitution, the more units sit in that dead volume. Insulin syringes with a fixed needle nearly eliminate this; a luer-lock syringe with a separate draw-up needle is the worst offender.
- Reconstitution loss. Foaming from injecting saline too forcefully, over-draw, and sloppy transfer all shave units off the top before a single patient is treated.
- Expiration. Reconstituted toxin has a limited in-use window. If you can't run a vial across enough patients inside that window, the remainder goes in the sharps container.
- Uncharged top-offs. The two units here, the four units there at a two-week follow-up. Generous, and entirely invisible on the P&L until you add up a year of it.
The vial-splitting break-even
Here's the math that should drive your booking template, not just your clinical protocol. If a vial costs you ~$550 loaded and you bill all 100 units, your realized cost is $5.50. Waste eight units and you billed 92 — realized cost jumps to ~$5.98, a 9% increase you never see because it never appears as a line item. It's simply margin that didn't show up.
Multiply that by several hundred vials a year and the "rounding error" becomes a real number — often four to five figures of recovered margin sitting inside your reconstitution habit.
What to do
- Standardize one dilution per product, across every injector. Consistency is what kills variance and waste. Let injectors have a clinical opinion; don't let the business run five different protocols.
- Draw with unit-marked insulin syringes (0.5 mL/50-unit or 0.3 mL/30-unit). They cut dead-space loss and remove the mental math that produces dosing drift.
- Track realized units billed per vial monthly — units billed divided by vials opened. Anything under ~92% is a leak; find it.
- Cluster your tox bookings so a reconstituted vial runs across multiple patients inside its stability window instead of expiring half-used.
- Reconcile rebate capture at the vial level so your "loaded cost" is the real number, not the one you assume.
None of this changes a single clinical outcome. It changes whether the product you already bought turns into revenue or into red biohazard bags — and over a year, that's one of the cleanest margin recoveries in the building.
Frequently asked questions
Does a higher dilution make Botox weaker?
No. The number of units in the vial is fixed regardless of saline volume. Higher dilution spreads the same dose over a larger injection volume, which increases the field of effect (diffusion) — a clinical and technique consideration, not a change in potency.
What is a 'standard' neurotoxin dilution?
There is no single standard. Common practice runs anywhere from 1 mL to 4 mL of preservative (bacteriostatic) saline per 100-unit vial, with 2 to 2.5 mL the most common compromise between dosing precision and diffusion control. The right move for a business is to standardize one dilution per product across every injector.
How much neurotoxin do practices typically waste per vial?
A well-tracked room keeps unbilled loss under roughly 5 to 8% — dead space, reconstitution loss, and the occasional comped touch-up. Rooms that don't measure it can quietly lose 10 to 15% or more to hub waste, expiration of reconstituted product, and uncharged 'top-offs.'
Can I charge patients for wasted units?
In cash aesthetics you bill for units injected, not units wasted — so unbilled product is simply absorbed as cost. That's exactly why realized cost-per-unit (purchase cost divided by units actually billed), not list price, is the number to manage.
